News
NBY
0.2633
+5.32%
0.0133
NovaBay Pharmaceuticals: Q1 Earnings Insights
NovaBay Pharmaceuticals (AMEX:NBY) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/12 21:12
NovaBay GAAP EPS of $0.00 beats by $0.03, revenue of $2.63M misses by $0.63M
NovaBay press release (NYSE:NBY): Q1 GAAP EPS of $0.00 beats by $0.03. Revenue of $2.63M (+45.3% Y/Y) misses by $0.63M.
Seekingalpha · 05/12 20:17
NovaBay Pharmaceuticals Q1 EPS $0.00 Beats $(0.03) Est., Sales $2.60M Miss $3.26M Estimate
NovaBay Pharmaceuticals (AMEX:NBY) reported quarterly sales of $2.60 million which missed the analyst consensus estimate of $3.26 million by 20.25 percent. This is a 43.88 percent increase over sales of $1.81 million
Benzinga · 05/12 20:10
-- Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.6M, vs. Street Est of $3.26M
MT Newswires · 05/12 16:28
NovaBay Q1 2022 Earnings Preview
NovaBay (NBY) is scheduled to announce Q1 earnings results on Thursday, May 12th, after market close. The consensus EPS Estimate is -$0.03 and the consensus Revenue Estimate is $3.26M (+80.1%
Seekingalpha · 05/11 21:35
Earnings Outlook For NovaBay Pharmaceuticals
NovaBay Pharmaceuticals (AMEX:NBY) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that NovaBay Pharmaceuticals will report an earnings per share (EP...
Benzinga · 05/11 17:04
NovaBay introduces new skincare products with anti-aging formulations
NovaBay Pharmaceuticals (NYSE:NBY) said it expanded its top-selling Kakadu C and Calm Cool + Corrected product lines by introducing new products with anti-aging ingredients to help reduce the appearance of
Seekingalpha · 05/09 11:29
NovaBay Pharmaceuticals Expands Top-Selling DERMAdoctor Kakadu C And Calm Cool + Corrected Collections With New Anti-Aging Formulations
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the expansion of its top-selling
Benzinga · 05/09 10:54
Top Premarket Gainers
MT Newswires · 04/26 08:07
NovaBay Pharmaceuticals CEO Issues Letter To Stockholders
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders: To My Fellow Stockholders: I am pleased to report that we have made
Benzinga · 04/25 10:50
NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
EMERYVILLE, Calif., April 25, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders:
Business Wire · 04/25 10:50
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) rose 31.9% to $3.35 in pre-market trading after jumping around 25% on Wednesday.
Benzinga · 04/21 10:22
23 Stocks Moving in Tuesday's Pre-Market Session
Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss.
Benzinga · 04/19 10:37
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to QVC® to Discuss DERMAdoctor’s Eczema Treatment
EMERYVILLE, Calif., April 11, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that Chief Product Officer Audrey Kunin, MD w...
Business Wire · 04/11 10:50
NovaBay Pharmaceuticals Introduces Hydrating Cleansing Oil to its DERMAdoctor Calm Cool + Corrected Product Line
EMERYVILLE, Calif., April 01, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the launch of Hydrating Cleans...
Business Wire · 04/01 10:50
NovaBay Pharma down on Q4 revenue miss
NovaBay Pharma (NBY -2.2%) posted lower-than-expected Q4 revenue Net product revenue for the quarter rose 40% to $2.6 million, but missed estimates by $0.71M. The company recorded $1.6M from Avenova spray sales,
Seekingalpha · 03/30 19:19
NovaBay Pharmaceuticals's Return On Capital Employed Insights
According to Benzinga Pro data, during Q4, NovaBay Pharmaceuticals (AMEX:NBY) posted sales of $2.64 million. Earnings were up 93.1%, but NovaBay Pharmaceuticals still reported an overall loss of $158.00 thousand.
Benzinga · 03/30 14:10
NovaBay GAAP EPS of -$0.02 beats by $0.03, revenue of $2.64M misses by $0.71M
NovaBay press release (NYSE:NBY): Q4 GAAP EPS of -$0.02 beats by $0.03. Revenue of $2.64M (+39.7% Y/Y) misses by $0.71M. Shares +1.56%.
Seekingalpha · 03/29 20:25
NovaBay Pharmaceuticals Q4 EPS $(0.02) Beats $(0.05) Estimate, Sales $2.60M Miss $3.34M Estimate
NovaBay Pharmaceuticals (AMEX:NBY) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. This is a 50 percent increase over losses of $(0.04) per share from
Benzinga · 03/29 20:12
-- Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q4 Revenue $2.6M, vs. Street Est of $3.35M
MT Newswires · 03/29 16:20
More
Webull provides a variety of real-time NBY stock news. You can receive the latest news about Novabay Pharma through multiple platforms. This information may help you make smarter investment decisions.
About NBY
NovaBay Pharmaceuticals, Inc. is a medical device company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is a solution of hypochlorous acid that acts as an antimicrobial preservative in solution and has been shown to neutralize bacterial toxins in laboratory tests. It develops additional products containing its hypochlorous acid, including NeutroPhase and PhaseOne for the wound care market. The Company's dermatology product includes CelleRx Clinical Reset, which is a facial spray that disrupts the layer of bacteria that settles and grows on the face. Its wound care business includes the business of NeutroPhase and PhaseOne product, which are used for the cleansing and irrigation of intraoperative pocket lavage, stasis ulcers, leg ulcers, diabetic foot ulcers, minor burns, superficial abrasions, wounds and moistening absorbent wound dressings.